Invivyd, Inc. (IVVD) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies (mAbs) for viral infectious diseases, primarily SARS-CoV-2. In March 2024, the company received Emergency Use Authorization (EUA) from the FDA for PEMGARDA (pemivibart) for pre-exposure prophylaxis of COVID-19 in immunocompromised patients. The company operates as an emerging growth company and has incurred significant losses since inception.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $2.3 million | $2.3 million | $0 |
| Net Loss | $(47.2) million | $(90.7) million | $(85.5) million |
| Net Loss Per Share | $(0.40) | $(0.77) | $(0.78) |
| Operating Cash Flow | Not provided for Q2 | $(91.8) million | $(78.6) million |
| Cash and Equivalents (End of Period) | $147.9 million | ||
| Accumulated Deficit | $(822.8) million |
Cost of Product Revenue: $0.1 million for the three and six months ended June 30, 2024.
Research & Development (R&D): $30.3 million (Q2) and $61.5 million (YTD).
Selling, General & Administrative (SG&A): $21.1 million (Q2) and $36.0 million (YTD).
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $2.3 million in product revenue for the first time, driven by sales of PEMGARDA following the March 2024 EUA. There was no revenue in the comparable 2023 periods.
- R&D Expenses: Decreased by $13.3 million in Q2 2024 compared to Q2 2023. This reduction was primarily due to a $29.1 million decrease in contract costs for commercial manufacturing of the VYD222 program, partially offset by $17.2 million in new costs for the VYD2311 program.
- SG&A Expenses: Increased by $11.0 million in Q2 2024 compared to Q2 2023. The increase was driven by higher personnel costs (including $4.5 million in stock-based compensation related to the accelerated vesting of the former CEO's options) and increased professional fees related to commercialization.
- Inventory: Inventory increased to $5.3 million as of June 30, 2024, from $0 at year-end 2023, as the company began capitalizing manufacturing costs post-EUA.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Based on current plans and excluding future revenue or financing, cash is insufficient to fund operations beyond one year from the filing date.
- Regulatory Updates: In July 2024, the company submitted a request to amend the PEMGARDA EUA to include treatment of mild-to-moderate symptomatic COVID-19. Additionally, a potential contamination event at a third-party assay vendor regarding potency data for the JN.1 variant may require revisions to the PEMGARDA Fact Sheet; the impact on the EUA remains uncertain.
- Capital Requirements: The company expects to require additional funding through equity offerings, debt, or collaborations. In February 2024, it raised $39.3 million via an "at-the-market" offering; $34.5 million remains available under this facility.
- Legal Proceedings: A securities class action lawsuit (Brill v. Invivyd, Inc.) regarding statements on ADG20's effectiveness against the Omicron variant is ongoing. The company intends to vigorously defend the action.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $147.9 million cash balance against the stated burn rate and the "substantial doubt" disclosure.
- PEMGARDA Commercialization: Assess the sustainability of the $2.3 million revenue run rate and the impact of the potential assay contamination issue on the EUA status.
- Contractual Obligations: Review the $52.6 million in noncancelable purchase obligations for commercial manufacturing with WuXi Biologics due in 2024-2025.
- Stock-Based Compensation: Note the $5.5 million one-time expense in Q2 related to the former CEO's separation and accelerated vesting.
- Pipeline Progress: Monitor the advancement of the VYD2311 candidate, which incurred $17.2 million in R&D costs in Q2 2024.